Pharma Invest, Chinese Group Partner for Drug Technology Transfer
Pharma Invest SPA, an Algerian company specializing in pharmaceutical production, has signed a partnership and cooperation agreement with China's Yangtze River Pharmaceutical Group. The agreement aims to transfer modern expertise and technologies for producing raw materials used in drug manufacturing and to develop innovative drugs. This initiative is intended to enhance national industrial and technological capabilities and support the path towards achieving health sovereignty. The Minister of Pharmaceutical Industry, Wassim Guidri, supervised the signing ceremony at the Ministry's headquarters, attended by sector executives and the CEO of the public group Saidal. This step falls within the framework of strengthening industrial and technological cooperation between Algerian companies and international partners, with a focus on developing and improving the quality of local production.
The agreement seeks to enable Pharma Invest SPA to benefit from advanced expertise and technologies, allowing it to control the production of pharmaceutical raw materials. Additionally, the partnership will provide support for the development and production of innovative drugs, thereby facilitating technology transfer and expanding national production capacities within the pharmaceutical sector. This collaboration underscores Algeria's commitment to self-sufficiency and innovation in its vital health industry.
In a related development, preliminary outlines were established during the meeting for an anticipated cooperation agreement between the public group Saidal and Pharma Invest SPA. This future agreement aims to foster collaboration in the production and distribution of high value-added medicines, opening new avenues for integration among national pharmaceutical entities. On this occasion, the Minister of Pharmaceutical Industry commended initiatives that direct the national pharmaceutical industry towards producing innovative drugs and mastering advanced technologies for raw material production, emphasizing the importance of these directions in strengthening national capacities and achieving health sovereignty.
